业绩亏损中的达安基因，间接控股股东要换人了

Core Viewpoint - The indirect controlling shareholder of Daan Gene will change from Guangzhou Financial Holdings Group to Guangzhou Pharmaceutical Group, following the acquisition of a 11.04% stake in Nanjing Pharmaceutical by Guangzhou Pharmaceutical Group [1][3]. Group 1: Shareholder Changes - Guangzhou Pharmaceutical Group will acquire 100% of Guangzhou Guangyong Technology Development Co., which holds 233 million shares of Daan Gene, and will also acquire an additional 70.17 million shares from both Guangzhou Financial Holdings and Guangzhou Health Investment, resulting in a total control of 374 million shares, accounting for 26.63% of Daan Gene's total share capital [1][3]. - The actual controller of Daan Gene will remain the Guangzhou Municipal Government, despite the change in indirect controlling shareholder, which has garnered significant attention [3]. Group 2: Financial Performance - Daan Gene's net profit attributable to shareholders is expected to decline by over 90% in 2023 and 2024, with a projected loss of 925 million yuan in 2024 [4]. - For the first three quarters of 2025, Daan Gene reported a net loss of 142 million yuan, largely due to asset impairment provisions totaling 180 million yuan, primarily related to receivables [4]. Group 3: Strategic Direction - The change in ownership aims to optimize the layout of state-owned capital and promote sustainable development through industry integration [4]. - Under the leadership of Li Xiaojun, who took over as chairman in November 2024, Guangzhou Pharmaceutical Group has been actively pursuing capital investments, including a recent acquisition of 11.04% of Nanjing Pharmaceutical [5]. - Guangzhou Pharmaceutical Group is focusing on modernization, digitalization, technological advancement, and internationalization as part of its strategic direction [5].